ADAP - Why Adaptimmune Therapeutics Stock Crushed It in May
Adaptimmune Therapeutics (NASDAQ: ADAP), a clinical-stage biotech, saw its shares gain an astounding 230% over the month of May, according to data from S&P Global Market Intelligence. The biotech's shares took flight late last month following a presentation at the American Society for Clinical Oncology annual meeting highlighting the progress of its specific peptide enhanced affinity receptor (SPEAR) T-cell platform in solid tumors.
What appears to have gotten investors truly excited was the news that Adaptimmune's most advanced clinical candidate, ADP-A2M4, reportedly produced durable responses in patients with synovial sarcoma. That's important because the company plans to use the therapy's ongoing trial as the basis for an accelerated regulatory filing, perhaps as soon as next year.
Image source: Getty Images.